Azopt Brinzolamide Eye Drops

1. Indications and Usage
Glaucoma and Ocular Hypertension:
Treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
It can be used as a monotherapy or as a concomitant treatment with beta-blockers.
2. Dosage and Administration
Route of Administration:
For Ophthalmic Use ONLY.
Recommended Dosage:
Standard Dose: One drop in the affected eye(s) three times daily.
Critical Administration Instructions:
Shake Well: This medication is a suspension. Shake the bottle well before each use.
Contact Lenses: Remove contact lenses before instillation and wait at least 15 minutes before reinserting, as the preservative (benzalkonium chloride) may be absorbed by soft lenses.
Systemic Absorption Reduction: After instillation, apply pressure to the lacrimal sac (nasolacrimal occlusion) or gently close the eye for 1–2 minutes. This reduces systemic absorption and potential side effects.
3. Mechanism of Action
Carbonic Anhydrase Inhibition:
Brinzolamide is a potent inhibitor of carbonic anhydrase II (CA-II).
Reduction of Aqueous Humor Production:
In the eye, CA-II is present in the ciliary processes. By inhibiting this enzyme, Brinzolamide reduces the secretion of bicarbonate ions, which subsequently decreases the transport of sodium and water.
Therapeutic Result: This leads to a reduction in the production of aqueous humor, thereby lowering intraocular pressure (IOP).
4. Safety and Warnings
Sulfonamide Sensitivity:
Although administered topically, Brinzolamide is a sulfonamide and is absorbed systemically.
Action: Serious skin reactions (e.g., Stevens-Johnson Syndrome) and hypersensitivity reactions may occur.
Renal Impairment:
Contraindicated in patients with severe renal impairment (e.g., creatinine clearance < 30 mL/min) or hyperchloremic acidosis, as the drug is excreted by the kidneys and may accumulate.
Ocular Surface Toxicity:
Long-term use may cause ocular surface irritation or corneal edema in patients with compromised corneal endothelium (e.g., Fuchs’ dystrophy).
5.Adverse Reactions
Most Common:
Local: Transient blurred vision (immediately after instillation), bitter taste (metallic taste), ocular burning/stinging, and conjunctival hyperemia.
Systemic: Headache, nausea, and dizziness.
6.Drug Interactions
Oral Carbonic Anhydrase Inhibitors:
Do not use concomitantly with oral CA inhibitors (e.g., acetazolamide) due to the potential for additive systemic effects (acidosis).
Topical Beta-Blockers:
No significant interaction observed; often used together for additive IOP lowering.
Ophthalmic Drugs:
If using more than one topical drug, administer at least 10 minutes apart.
7.Pharmaceutical Information
Chemical Composition:
Active Ingredient: Brinzolamide (1% w/v).
Appearance: White to off-white, uniform suspension.
Preservative: Contains Benzalkonium Chloride.
Storage: Store at 15–25°C (59–77°F).